API Apalutamide

Apalutamide More Info

Mechanism of Action

Apalutamide works by competitively binding to the androgen receptor in prostate cancer cells. It blocks the binding of androgens such as testosterone to the receptor, thereby preventing the activation of androgen - regulated genes. This inhibits the growth and proliferation of prostate cancer cells and slows down the progression of the disease.

Clinical Applications

Prostate Cancer Treatment: It is mainly used for the treatment of non - metastatic castration - resistant prostate cancer (nmCRPC) and metastatic castration - sensitive prostate cancer (mCSPC). In patients with nmCRPC, apalutamide has been shown to significantly prolong metastasis - free survival. In mCSPC, when combined with androgen - deprivation therapy, it can improve overall survival and other clinical endpoints compared to androgen - deprivation therapy alone.

Administration and Dosage

The recommended dosage of apalutamide is 240 mg (four 60 - mg tablets) taken orally once daily. It can be taken with or without food. Treatment should be continued until disease progression or unacceptable toxicity occurs. Dose adjustments may be required in patients with certain hepatic or renal impairments.

Side Effects and Precautions

Common Side Effects: Include fatigue, rash, diarrhea, nausea, hypertension, hot flashes, and decreased appetite. Some patients may also experience anemia, peripheral edema, and musculoskeletal pain.

Serious Side Effects: There is a risk of seizures, which is a relatively rare but serious side effect. Apalutamide may also affect lipid metabolism, leading to increased levels of cholesterol and triglycerides. It can cause liver function abnormalities, so regular monitoring of liver enzymes is necessary during treatment.

Precautions: Patients should be informed of the risk of seizures and advised to avoid activities that require high attention and coordination until they know how the drug affects them. Regular monitoring of blood pressure, lipids, and liver function is essential to detect and manage any potential adverse effects promptly. Women of childbearing potential should avoid exposure to apalutamide, as it may cause fetal harm.

Apalutamide has played an important role in the treatment of prostate cancer, offering new treatment options and improving the prognosis for many patients. However, like any drug, it should be used under the guidance of a doctor, and patients need to be closely monitored for side effects and treatment efficacy.